Adenosine A1 receptor agonists as clinically viable agents for treatment of ischemic brain disorders

Annals of the New York Academy of Sciences

Volumn 825, Issue , 1997, Pages 23-29

  Bischofberger, Norbert ^a   Jacobson, Kenneth A ^b   Von Lubitz, Dag K J E ^b  

^a GILEAD SCIENCES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE AMINE CONGENER; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT;

BLOOD PRESSURE; BRAIN ISCHEMIA; CARDIOVASCULAR SYSTEM; CELL SURVIVAL; CONFERENCE PAPER; GERBIL; NERVE CELL; NONHUMAN; ANIMAL; BRAIN; DRUG EFFECT; DRUG POTENTIATION; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TRANSIENT ISCHEMIC ATTACK;

GERBILLINAE;

ADENOSINE; ANIMALS; BRAIN; BRAIN ISCHEMIA; CELL SURVIVAL; HUMANS; ISCHEMIC ATTACK, TRANSIENT; NEURONS; NEUROPROTECTIVE AGENTS; RECEPTORS, PURINERGIC P1;

EID: 0030613748     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1997.tb48411.x     Document Type: Conference Paper

References (34)

1. RUDOLPHI, K. A., P. SCHUBERT, F. E. PARKINSON & B. B. FREDHOLM. 1992. Cerebrovasc. Brain Metab. Rev. 4: 346-369.
2. RUDOLPHI, K. A., P. SCHUBERT, F. E. PARKINSON & B. B. FREDHOLM. 1992. Trends Pharmacol. Sci. 13(12): 439-445.
3. MILLER, L. P. & C. HSU. 1992. J. Neurotrauma 9(Suppl. 2): S563-S577.
4. VON LUBITZ, D. K. J. E., M. F. CARTER, M. BEENHAKKER, R. C.-S. LIN & K. A. JACOBSON. 1995. Adenosine: a prototherapeutic concept in neurodegeneration. In Neuroprotective Agents: Clinical and Experimental Aspects. B. Trembly & W. Slikker, Jr., Eds. Ann. N. Y. Acad. Sci. 765: 163-178.
5. SCHUBERT, P. & G. W. KREUTZBERG. 1990. Neuroprotective mechanisms of endogenous adenosine action and pharmacological implications. In Pharmacology of Cerebral Ischemia. J. Krieglstein & H. Oberpichler, Eds. 417. Wissenschaftliche Verlagsgesellschaft. Stuttgart.
6. VON LUBITZ, D. K. J. E. & P. J. MARANGOS. 1992. In Emerging Strategies in Neuroprotection. P. J. Marangos & H. Lal, Eds. 151-186. Birkhäuser. Basel.
7. VON LUBITZ, D. K. J. E. 1997. Adenosine and acute treatment of ischemic brain disorders - put out more flags! In Purinergic Approaches in Experimental Therapeutics. K. A. Jacobson & M. F. Jarvis, Eds. Wiley. New York. In press.
8. RUDOLPHI, K. A. & P. SCHUBERT 1996. Purinergic interventions in traumatic and ischemic injury. In Novel Therapies for CNS Injuries, Rationales and Results. P. L. Peterson & J. W. Phillis, Eds. 327. CRC Press. Boca Raton.
9. JACOBSON, K. A., D. K. J. E. VON LUBITZ, J. W. DALY & B. B. FREDHOLM. 1996. Trends Pharmacol. Sci. 17: 108-113.
10. KOSTOPOULOS, G. K. & J. W. PHILLIS. 1977. Exp. Neurol. 55: 719-724.
11. VON LUBITZ, D. K. J. E. & P. J. MARANGOS. 1990. J. Mol. Neurosci. 2(1): 53-59.
12. PHILLIS, J. W. 1991. Adenosine and Adenine Nucleotides as Regulators of Cellular Functions. CRC Press. Boca Raton.
13. JI, X. D., D. K. J. E. VON LUBITZ, M. OLAH, G. L. STILES, & K. A. JACOBSON. 1994. Drug Dev. Res. 33: 51-59.
14. VAN GALEN, P. J. M., G. L. STILES, G. MICHAELS & K. A. JACOBSON. 1992. Med. Res. Rev. 12: 423-471.
15. JACOBSON, K. A. & F. SUZUKI. 1997. Drug Dev. Res. In press.
16. VAN CALKER D., M. MÜLLER & G. HAMPRECHT. 1979. J. Neurochem. 33: 999-1005.
17. RAMKUMAR, V., G. L. STILES, M. A. BEAVEN & H. ALI. 1993. J. Biol. Chem. 268: 16887-16890.
18. JARVIS, M. F. & M. WILLIAMS. 1989. Eur. J. Pharmacol. 168: 243-246.
19. TRUSSEL, L. O. & M. B. JACKSON. 1985. Proc. Natl. Acad. Sci. USA 82: 4857-4860.
20. MAGER, R., S. FERRONI & P. SCHUBERT. 1990. Brain Res. 532: 58-62.
21. SCHUBERT, P., U. HEINEMANN & R. KOLB. 1986. Brain Res. 376: 382-386.
22. FREDHOLM B. B. & T. V. DUNWIDDIE. 1988. Trends Pharmacol. Sci. 9: 130-134.
23. DUNWIDDIE, T. V. 1980. Epilepsia 21: 541-548.
24. DUNWIDDIE, T. V. 1985. Intl. Rev. Neurobiol. 27: 63-139.
25. GOLDBERG, M. P., H. MONYER, J. H. WEISS & D. W. CHOI. 1988. Neurosci. Lett. 89: 323-327.
26. VON LUBITZ, D. K. J. E., R. C.-S. LIN, N. MELMAN, X.-D. JI, M. F. CARTER & K. A. JACOBSON. 1994. Eur. J. Pharmacol. 256: 161-167.
27. RUDOLPHI, K. A., M. KEIL & H. J. HINZE. 1987. J. Cereb. Blood Flow Metab. 7: 74-81.
28. KNUTSEN, L. J. S., J. LAU, H. PETERSEN, C. THOMSEN, J. W. WEIS, M. SHALMI, M. E. JUDGE, A. J. HANSEN & M. J. SHEARDOWN. 1997. J. Med. Chem. In press.
29. VON LUBITZ, D. K. J. E., I. A. PAUL, X.-D. JI, M. F. CARTER & K. A. JACOBSON. 1994. Eur. J. Pharmacol. 253: 95-99.
30. JACOBSON, K. A., K. L. KIRK, W. L. PADGETT & J. W. DALY 1985. J. Med. Chem. 28: 1341-1346.
31. VON LUBITZ, D. K. J. E., M. BEENHAKKER, R. C.-S. LIN, M. F. CARTER, I. A. PAUL, N. BISCHOFBERGER & K. A. JACOBSON. 1996. Eur. J. Pharmacol. 302(1-3): 43-48.
32. VON LUBITZ, D. K. J. E., R. C.-S. LIN, M. BEENHAKKER, M. BOYD, N. BISCHOFBERGER & K. A. JACOBSON. 1996. Eur. J. Pharmacol. In press.
33. BOYD, M., Y. MESHULAM, K. A. JACOBSON & D. K. J. E. VON LUBITZ. 1996. In Vitro, FASEB Abstracts. Washington, DC. April 14-17.
34. SCHUBERT P. & T. OGATA. 1996. J. Neurochem. 66(S2): S4.